Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s stock price fell 13.5% during mid-day trading on Monday . The company traded as low as C$0.15 and last traded at C$0.16. 1,437,130 shares traded hands during mid-day trading, an increase of 1,326% from the average session volume of 100,774 shares. The stock had previously closed at C$0.19.
Theralase Technologies Trading Down 16.2%
The firm has a market cap of C$39.84 million, a P/E ratio of -8.61 and a beta of -0.22. The stock has a 50 day simple moving average of C$0.20 and a 200-day simple moving average of C$0.20. The company has a current ratio of 1.91, a quick ratio of 3.40 and a debt-to-equity ratio of 14.85.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
See Also
- Five stocks we like better than Theralase Technologies
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook
- Stock Market Upgrades: What Are They?
- Why Circle Stock Is Falling—and Why Some Analysts See Big Upside
- Insider Trades May Not Tell You What You Think
- NVIDIA Nears Buy Zone as Rumors Swirl About China Chip Deal
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
